<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39362190</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0097</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>International archives of allergy and immunology</Title><ISOAbbreviation>Int Arch Allergy Immunol</ISOAbbreviation></Journal><ArticleTitle>Initial Experience of Long-Term Prophylaxis with Lanadelumab for Hereditary Angioedema in China: A Clinical Observation Study on Six Patients.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000541242</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Hereditary angioedema (HAE) is a rare genetic disorder caused by deficiency or dysfunction of C1-esterase inhibitor that is characterized by recurrent episodes of bradykinin-mediated edema. Lanadelumab has been the only available first-line therapy for long-term prophylaxis (LTP) of HAE in China since its approval in 2020. The present study aimed to investigate the clinical efficacy and safety of lanadelumab for LTP in Chinese patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective clinical data were collected for the 6 patients and used to examine the frequency of attack symptoms, disease-related loss of work days, and quality of life before and after LTP with lanadelumab. Health-related quality of life was assessed using the Dermatology Life Quality Index (DLQI) and the Angioedema Quality of Life Questionnaire (AE-QoL).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lanadelumab led to reductions of 97.8% and 98.5% in the attack rate and treated attack rate, respectively. All patients exhibited significant improvements in AE-QoL and DLQI scores (100% reduction rates) during the early treatment period (4 weeks and 2 weeks, respectively) and in missed work days/year (98.9% reduction rate). The efficacy of lanadelumab remained stable during COVID-19 vaccination and infection. No serious/severe treatment-emergent adverse events occurred during lanadelumab treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study is the first report that demonstrates the clinical efficacy of lanadelumab and safety of LTP in HAE patients from Chinese mainland. A reasonable dosage plan can ensure a quick and long-lasting protective role of lanadelumab against HAE attacks, during COVID-19 pandemic period.</AbstractText><CopyrightInformation>Â© 2024 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Wo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 2320001@zju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diao</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Boyun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yongfang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bohui</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Liuya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Outpatient Care, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yongmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Rongfei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Allergy, Tongji Hospital of Huazhong University of Science and Technology Tongji Medical College, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Allergy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int Arch Allergy Immunol</MedlineTA><NlmUniqueID>9211652</NlmUniqueID><ISSNLinking>1018-2438</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chinese patients</Keyword><Keyword MajorTopicYN="N">Hereditary angioedema</Keyword><Keyword MajorTopicYN="N">Lanadelumab</Keyword><Keyword MajorTopicYN="N">Prophylaxis</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39362190</ArticleId><ArticleId IdType="doi">10.1159/000541242</ArticleId><ArticleId IdType="pii">000541242</ArticleId></ArticleIdList></PubmedData></PubmedArticle>